Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer
Details : FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.
Product Name : Tepylute
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
